Neoadjuvant Treatment of Colon Cancer

Inclusion Criteria: * Histologically verified locally advanced T3 or T4 colon cancer assessed by CT scan * Analysis of KRAS, BRAF, PIK3CA * Age ≥18 år * Performance status ≤ 2 * Hematology * ANC ≥ 1.5x10\^9/l. Thrombocytes ≥ 100x10\^9/l. * Biochemistry * Bilirubinaemia ≤ 3 x UNL. ALAT ≤ 5 x UNL * Consent to translational research * Fertile women must present a negative pregnancy test and use secure birth control during and 3 months after treatment. * Written and orally informed consent. Exclusion Criteria: * Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment, active severe infections or other concurrent disease. * Peripheral neuropathy NCI grade \>1 * Other malignant disease within 5 years prior to enrollment, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ * Other investigational treatment within 30 days prior to treatment start * History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan. * Bleeding tumors * Hypersensitivity to one or more of the substances